The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer
BackgroundBorderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.796317/full |
| _version_ | 1798021597676699648 |
|---|---|
| author | Nervana Hussien Rasha S. Hussien Darine Helmy Amin Saad Mohamed El Kassas Walid F. Elkhatib Walid F. Elkhatib Mai Ezz El Din |
| author_facet | Nervana Hussien Rasha S. Hussien Darine Helmy Amin Saad Mohamed El Kassas Walid F. Elkhatib Walid F. Elkhatib Mai Ezz El Din |
| author_sort | Nervana Hussien |
| collection | DOAJ |
| description | BackgroundBorderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat difficult to assess by current radiological parameters.AimTo evaluate the role of Magnetic Resonance Imaging (MRI) pancreatic protocol, including Diffusion-Weighted Imaging (DWI), in patients with BRPC receiving neoadjuvant therapy, and further compare it to RECIST criteria and outcome.MethodsHistologically confirmed BRPC patients were prospectively included. DWI-MRI was performed pre- and post-therapy. Clinical characteristics with ensuing operability were recorded and correlated to radiological RECIST/apparent diffusion coefficient (ADC) change, preoperative therapy administrated, surgical resection status, and survival.ResultsOut of 30 BRPC cases, only 11 (36.7%) ultimately underwent pancreaticoduodenectomy. Attaining a stationary or stable disease via ADC/RECIST was achieved in the majority of cases (60%/53.3% respectively). Of the 12 patients (40%) who achieved a regression by ADC, 11 underwent surgery with an R0 status. These surgical cases showed variable RECIST responses (PR=5, SD=4, PD=3). Responders by ADC to neoadjuvant therapy were significantly associated to presenting with abdominal pain (p =0.07), a decline in post-therapy CA19-9 (p<0.001), going through surgery (p<0.001), and even achieving better survival (p<0.001 vs. 0.66).ConclusionDWI-MRI ADC picked up patients most likely to undergo a successful operative procedure better than traditional RECIST criteria. An algorithm incorporating novel radiological advances with CA19-9 deserves further assessment in future studies. |
| first_indexed | 2024-04-11T17:16:10Z |
| format | Article |
| id | doaj.art-b8bfb6dc48c74e458705e4ea74c60514 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T17:16:10Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b8bfb6dc48c74e458705e4ea74c605142022-12-22T04:12:40ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.796317796317The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic CancerNervana Hussien0Rasha S. Hussien1Darine Helmy Amin Saad2Mohamed El Kassas3Walid F. Elkhatib4Walid F. Elkhatib5Mai Ezz El Din6Department of Clinical Oncology, Faculty of Medicine, Helwan University, Cairo, EgyptDepartment of Radiology, Faculty of Medicine, Ain Shams University, Cairo, EgyptDepartment of Biological Anthropology, National Research Centre, Cairo, EgyptDepartment of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo, EgyptDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, EgyptDepartment of Microbiology & Immunology, Faculty of Pharmacy, Galala University, Suez, EgyptDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, EgyptBackgroundBorderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat difficult to assess by current radiological parameters.AimTo evaluate the role of Magnetic Resonance Imaging (MRI) pancreatic protocol, including Diffusion-Weighted Imaging (DWI), in patients with BRPC receiving neoadjuvant therapy, and further compare it to RECIST criteria and outcome.MethodsHistologically confirmed BRPC patients were prospectively included. DWI-MRI was performed pre- and post-therapy. Clinical characteristics with ensuing operability were recorded and correlated to radiological RECIST/apparent diffusion coefficient (ADC) change, preoperative therapy administrated, surgical resection status, and survival.ResultsOut of 30 BRPC cases, only 11 (36.7%) ultimately underwent pancreaticoduodenectomy. Attaining a stationary or stable disease via ADC/RECIST was achieved in the majority of cases (60%/53.3% respectively). Of the 12 patients (40%) who achieved a regression by ADC, 11 underwent surgery with an R0 status. These surgical cases showed variable RECIST responses (PR=5, SD=4, PD=3). Responders by ADC to neoadjuvant therapy were significantly associated to presenting with abdominal pain (p =0.07), a decline in post-therapy CA19-9 (p<0.001), going through surgery (p<0.001), and even achieving better survival (p<0.001 vs. 0.66).ConclusionDWI-MRI ADC picked up patients most likely to undergo a successful operative procedure better than traditional RECIST criteria. An algorithm incorporating novel radiological advances with CA19-9 deserves further assessment in future studies.https://www.frontiersin.org/articles/10.3389/fonc.2021.796317/fullborderline resectable pancreatic cancerADCradiological assessmentRECIST criteriaDWI-MRI |
| spellingShingle | Nervana Hussien Rasha S. Hussien Darine Helmy Amin Saad Mohamed El Kassas Walid F. Elkhatib Walid F. Elkhatib Mai Ezz El Din The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer Frontiers in Oncology borderline resectable pancreatic cancer ADC radiological assessment RECIST criteria DWI-MRI |
| title | The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer |
| title_full | The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer |
| title_fullStr | The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer |
| title_full_unstemmed | The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer |
| title_short | The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer |
| title_sort | role of mri pancreatic protocol in assessing response to neoadjuvant therapy for patients with borderline resectable pancreatic cancer |
| topic | borderline resectable pancreatic cancer ADC radiological assessment RECIST criteria DWI-MRI |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.796317/full |
| work_keys_str_mv | AT nervanahussien theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT rashashussien theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT darinehelmyaminsaad theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT mohamedelkassas theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT walidfelkhatib theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT walidfelkhatib theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT maiezzeldin theroleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT nervanahussien roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT rashashussien roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT darinehelmyaminsaad roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT mohamedelkassas roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT walidfelkhatib roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT walidfelkhatib roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer AT maiezzeldin roleofmripancreaticprotocolinassessingresponsetoneoadjuvanttherapyforpatientswithborderlineresectablepancreaticcancer |